AtheroNova Announces Pre-IND Filing Under Section 505(b)(2)
July 15, 2014 08:00 ET
|
AtheroNova Inc.
IRVINE, Calif., July 15, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova Announces Russian Ministry of Healthcare Approval for Initiation of Phase 1b Trial Investigating AHRO-001
May 28, 2014 09:00 ET
|
AtheroNova Inc.
IRVINE, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova Announces Q1 2014 Financial Results/Highlights
May 19, 2014 09:00 ET
|
AtheroNova Inc.
IRVINE, Calif., May 19, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHROD), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova Receives Notice of Issuance of Its 2nd US Patent 8,697,633
May 08, 2014 09:00 ET
|
AtheroNova Inc.
IRVINE, Calif., May 8, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHROD), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova 1-for-10 Reverse Stock Split Effective
April 22, 2014 09:00 ET
|
AtheroNova Inc.
IRVINE, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova Appoints Dr. Randolph M. Johnson as Chief Operating Officer
April 08, 2014 09:00 ET
|
AtheroNova Inc.
IRVINE, Calif., April 8, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova Announces 2013 Financial Results
March 06, 2014 08:30 ET
|
AtheroNova Inc.
IRVINE, Calif., March 6, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...
AtheroNova Announces Preliminary Positive Phase 1 Clinical Data From Lead Drug AHRO-001, a Potential Treatment for Atherosclerosis
February 27, 2014 08:30 ET
|
AtheroNova Inc.
IRVINE, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and...